NasdaqGS:NVCRMedical Equipment
NovoCure (NVCR) Is Up 9.7% After Raising 2026 Revenue Outlook And Posting Stronger Q1 Sales
In April 2026, NovoCure reported first-quarter 2026 results showing sales of US$174.06 million and a net loss of US$71.14 million, while also updating its full-year 2026 net revenue outlook to US$690 million–US$710 million from US$675 million–US$705 million.
The combination of stronger quarterly sales and a higher full-year revenue range gives investors fresh insight into how management views current demand for its tumor treating fields devices.
We’ll now examine how NovoCure’s higher 2026...